Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-10-22
1996-12-03
Dees, Jos e G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3142
Patent
active
055808921
ABSTRACT:
A pharmaceutical composition, useful for treating animals of the mammalian species, including humans, to treat diseases and conditions which normally respond to treatment with alpha.sub.2 adrenergic agents, contains as its active alpha.sub.2 adrenergic agent ingredient one or more compounds of the formula ##STR1## where X is 0, S or NH; n is an integer with the values of 0, 1 or 2; when n is 0 then R.sub.1 is lower alkyl having 1 to 6 carbon atoms and R.sub.2 is H or lower alkyl having 1 to 6 carbon atoms; when n is 1 or 2, then R.sub.1 and R.sub.2 both are methylene (CH.sub.2), or methylene substituted with an R.sub.5 group where R.sub.5 is lower alkyl of 1 to 6 carbons; R.sub.3 and R.sub.4 independently are H or lower alkyl having 1 to 6 carbons; R.sub.6 is H or lower alkyl of 1 to 6 carbons.
REFERENCES:
patent: 2027030 (1936-01-01), Englemann et al.
patent: 2876232 (1959-03-01), Bloom
patent: 3432600 (1969-03-01), Harvey, Jr. et al.
patent: 3453284 (1969-07-01), Harvey, Jr. et al.
patent: 3598833 (1971-08-01), Hiltmann et al.
patent: 3624092 (1971-11-01), Levitt et al.
patent: 3636219 (1972-01-01), Culik et al.
patent: 3679798 (1972-07-01), Culik et al.
patent: 3890319 (1975-06-01), Danielewicz et al.
patent: 3907996 (1975-09-01), Griss et al.
patent: 3993766 (1976-11-01), Behner et al.
patent: 4256755 (1981-03-01), Smith, Jr.
patent: 4515800 (1985-05-01), Cavero et al.
patent: 4587257 (1986-05-01), DeSantis et al.
patent: 4683229 (1987-07-01), Demarinis et al.
patent: 5066664 (1991-11-01), Gluchowski
patent: 5091528 (1992-02-01), Gluchowski
patent: 5151440 (1992-09-01), Gluchowski
patent: 5180721 (1993-01-01), Burke
patent: 5252595 (1993-10-01), Gluchowski
Wollweber et al. Chem. Abstr., vol. 70, entry 47428f (1969) abstracting GB 1 132 409.
"Heteroaromatic Analogues of the alpha.sub.2 -Adrenoreceptor Partial Agonist Clonidine" J. Med. Chem., 1989, 32, 1627-1630, Chapleo et al.
"Possible Subdivision of Postsynaptic x-Adrenoceptors Mediating Pressor Responses in the Pithed Rat", Nauyn-Schmiedeberg's Archives of Pharmacology, 310, 189-193, (1979) Timmermans, et al.
"Pharmacologic Differentiation Between Pre- and Postjunctional x-adrenoceptors by SK & F 104078", Nauyn-Schmiedeberg's Archives of Pharmacology, 336, 415-418, (1987) Ruffolo, R., et al.
"Distribution and Function of Pheripheral--Adrenoceptors in the Cardiovascular System", Pharmacology Biochemistry & Behavior, 22, 827-833, (1985) Ruffolo, R.
"Clonidine and Related Analogues. Quantitative Correlations", Journal of Medicinal Chemistry, vol., 19, No. 8, pp. 1049-1053, (1976) B. Rouot, et al.
K. Darmsataphone et al., Gastroenterology, vol. 86, No. 1, 1984, pp. 120--128.
Burke James E.
Garst Michael E.
Wheeler Larry A.
Allergan
Baran Robert J.
Cebulak Mary C.
Dees Jos e G.
Szekeres Gabor L.
LandOfFree
Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-785994